A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

NCT01576887 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped IDMC recommendation for safety concerns

Conditions

End-Stage Renal Disease
Type 2 Diabetes Mellitus

Interventions

DRUG: Bardoxolone Methyl 20 mg
DRUG: Placebo

Sponsor

Biogen